RESEARCH ARTICLE

Alzheimer's & Dementia®
THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION

Altered limbic functional connectivity in individuals with subjective cognitive decline: Converging and diverging findings across Chinese and German cohorts

Xueyan Jiang[1,2,3] | Xiaochen Hu[4] | Marcel Daamen[2] | Xiaoqi Wang[1] |
Chunqiu Fan[1] | Dix Meiberth[2,4] | Annika Spottke[2,5] | Sandra Roeske[2] |
Klaus Fliessbach[2,6] | Eike Jakob Spruth[7,8] | Slawek Altenstein[7,8] | Andrea Lohse[8] |
Niels Hansen[9] | Wenzel Glanz[10] | Enise I. Incesoy[10,11,12] | Laura Dobisch[10] |
Daniel Janowitz[13] | Boris-Stephan Rauchmann[14] | Alfredo Ramirez[2,6,15,16,17] |
Ingo Kilimann[18,19] | Matthias H. Munk[20,21] | Xiao Wang[22] |
Luisa-Sophie Schneider[22] | Tatjana Gabelin[22] | Nina Roy[2] |
Steffen Wolfsgruber[2,6] | Luca Kleineidam[2,6] | Stefan Hetzer[23] | Peter Dechent[24] |
Michael Ewers[25] | Klaus Scheffler[26] | Holger Amthauer[27] |
Ralph Buchert[27,28] | Markus Essler[29] | Alexander Drzezga[2,30,31] |
Axel Rominger[32,33] | Bernd J. Krause[34] | Matthias Reimold[35] |
Josef Priller[7,8,36,37] | Anja Schneider[2,6] | Jens Wiltfang[9,38,39] |
Katharina Buerger[13,25] | Robert Perneczky[14,25,40,41] | Stefan Teipel[18,19] |
Christoph Laske[20,42] | Oliver Peters[7,22] | Emrah Düzel[10,11] |
Michael Wagner[2,6] | Jiehui Jiang[43] | Frank Jessen[2,4,15] |
Henning Boecker[2,44] | Ying Han[1,3,45,46]

Correspondence
Xiaochen Hu, Department of Psychiatry and Psychotherapy, University of Cologne, Medical Faculty, Kerpener Strasse 62, 50924 Cologne, Germany.
Email: xiaochen.hu@uk-koeln.de

Ying Han, Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing 100053, China.
Email: hanying@xwh.ccmu.edu.cn

Xueyan Jiang and Xiaochen Hu share first authorship.

Henning Boecker and Ying Han share last authorship.

Abstract

INTRODUCTION: It remains unclear whether functional brain networks are consistently altered in individuals with subjective cognitive decline (SCD) of diverse ethnic and cultural backgrounds and whether the network alterations are associated with an amyloid burden.

METHODS: Cross-sectional resting-state functional magnetic resonance imaging connectivity (FC) and amyloid-positron emission tomography (PET) data from the Chinese Sino Longitudinal Study on Cognitive Decline and German DZNE Longitudinal Cognitive Impairment and Dementia cohorts were analyzed.

RESULTS: Limbic FC, particularly hippocampal connectivity with right insula, was consistently higher in SCD than in controls, and correlated with SCD-plus features.

Smaller SCD subcohorts with PET showed inconsistent amyloid positivity rates and FC–amyloid associations across cohorts.

DISCUSSION: Our results suggest an early adaptation of the limbic network in SCD, which may reflect increased awareness of cognitive decline, irrespective of amyloid pathology. Different amyloid positivity rates may indicate a heterogeneous underlying etiology in Eastern and Western SCD cohorts when applying current research criteria. Future studies should identify culture-specific features to enrich preclinical Alzheimer's disease in non-Western populations.

KEYWORDS
amyloid deposition, Centiloid, cross-cultural harmonization, functional connectivity, hippocampus, insula, subjective cognitive decline

Highlights

- Common limbic hyperconnectivity across Chinese and German subjective cognitive decline (SCD) cohorts was observed.
- Limbic hyperconnectivity may reflect awareness of cognition, irrespective of amyloid load.
- Further cross-cultural harmonization of SCD regarding Alzheimer's disease pathology is required.

1 | BACKGROUND

Subjective cognitive decline (SCD), a status in individuals of higher age with perceived cognitive decline without objective evidence for impairments on standardized cognitive tests, has been considered promising for early detection of Alzheimer's disease (AD).[1,2] Recently, SCD was recognized as a clinical indicator for the cognitive transition stage of the AD continuum, that is, between fully normal cognition and objectively detectable cognitive impairment.[3] Despite commonly observed increases in rates of incident AD dementia,[4] amyloid positivity rates vary considerably depending on specific sample characteristics.[5] For enrichment of preclinical AD, additional SCD-plus criteria, such as concerns regarding cognitive decline, were proposed.[1,2]

The SCD concept was mainly driven by research in Western cohorts.[1,2,5] SCD assessment does not rely on objective performance measures, but essentially on self-reports, which may be affected by language and cultural backgrounds.[1] Cultural factors, such as social stigmatization of cognitive problems, responding style on self-reported measures, and tolerance of slowly progressive cognitive decline in aging,[6] may influence the willingness and accuracy of self-reports on cognitive decline. Accordingly, it is unclear whether the current SCD research definition is equally suited for Eastern populations, or needs tailoring regarding cultural appropriateness and specificity for the target population.[7] To harmonize SCD research across cultures, Sino-German conferences took place (2016, 2017, 2019),[8] and Chinese SCD cohorts were established using a contemporary SCD research definition.[9–12] Beyond adherence to the general SCD defini-

tion, various SCD-related features[1,2] were coded, and their predictive value for amyloid burden was tested in Chinese SCD subjects.[13,14] Still, comparability between SCD individuals from both countries is unknown.

During a neurodegenerative process, the brain undergoes alterations from abnormally aggregated proteins and changes in neuronal networks to behavioral and cognitive symptoms.[15,16] Neuronal networks involving key limbic areas are particularly interesting in view of their critical role in processing emotions, memories, and other cognitive functions.[17] Limbic network alterations were previously observed along the AD continuum,[18–20] including SCD populations.[21] Beyond incipient atrophic[22,23] and hypometabolic alterations[24,25] in limbic areas, changes in network function at wakeful rest were frequently reported in SCD, although with conflicting results.[26] Both increases,[22,27–31] decreases,[32–35] and no differences[36] in functional connectivity (FC) involving key limbic areas were observed in SCD compared to cognitively normal controls (NC). Reasons for inconsistencies could be small sample sizes,[32] heterogeneous SCD definitions,[22,36] and divergent analytical techniques, such as seed-based approaches,[29] independent component analysis,[36] or topological network properties.[30] Furthermore, ethnicity can be an additional source of variance for functional network organization.[37,38]

There is also limited evidence regarding whether changes of limbic FC in SCD are related to brain amyloid burden. Higher amyloid burden was associated with decreased seed-based functional connectivity (sFC) between basal forebrain and limbic areas (i.e., hippocampus and thalamus),[39] increased sFC between the precuneus and

occipital regions,[40] and increased topological network properties within the default mode network (DMN).[30] A longitudinal study showed widespread increased FC within the DMN 24 months after baseline measurements. However, this was not modulated by baseline amyloid positivity.[41] Importantly, previous studies have not systematically examined whether amyloid burden–related FC changes are generalizable across ethnically diverse SCD samples.

For these reasons, the current study aimed at investigating FC between key limbic structures and the rest of the brain in two independent but similarly conceptualized SCD cohorts from Germany and China. FC changes in SCD with different ethnic and cultural backgrounds were evaluated using identical FC analytic approaches. Two complementary voxel-wise connectivity measures served as readouts of functional brain networks, a graph-based approach (i.e., weighted degree of connectivity [DC]) and a seed-based method (sFC). Weighted DC provides precise centrality characterization of functional brain networks and allows unbiased exploration of regions with abnormal global connectivity. The sFC estimates the interregional connectivity strength for characterizing the underlying mechanism of altered network integration for a specific brain region.[42,43] Therefore, this cross-ethnic study allowed us to determine (1) common limbic FC changes associated with SCD, regardless of ethnicity, and (2) distinct limbic FC changes associated with SCD specific to each ethnic cohort. Finally, (3) in SCD participants with available amyloid positron emission tomography (PET) data, relationships between limbic FC changes and cortical amyloid load were examined in each cohort separately.

> **RESEARCH IN CONTEXT**
>
> 1. **Systematic Review**: Accumulating evidence points toward aberrant limbic functional connectivity (FC) in subjective cognitive decline (SCD). The establishment of the current research framework of SCD is based on Western populations. Translation to other cultural contexts is still pending.
> 2. **Interpretation**: Limbic FC is consistently elevated in two large SCD cohorts from different ethnic and cultural backgrounds, suggesting common early brain network adaptations that may reflect an increased awareness of cognitive decline, not driven by amyloid pathology. Current cohort differences in brain amyloid burden may indicate a heterogeneous etiology in SCD defined by the current research definition, which may underlie the diverse functional reorganization between these two cohorts.
> 3. **Future Directions**: Further harmonizing the SCD concept across borders and cultures is necessary. Future work should identify culturally specific SCD features to achieve enrichment of preclinical Alzheimer's disease and guide future treatment and prevention in non-Western populations.

---

2 | METHODS AND MATERIALS

The current analysis included data from two independent studies, SILCODE (Sino Longitudinal Study on Cognitive Decline) from China and DELCODE (DZNE Longitudinal Cognitive Impairment and Dementia) from Germany: both are ongoing longitudinal observational studies aiming to diagnose, estimate, and predict cognitive decline in SCD subjects using multimodal data, including clinical information, neuropsychological assessments, biological markers, and neuroimaging.[9,43,44]

2.1 | Subjects

SCD groups in both cohorts were defined by self-perceived continuous cognitive decline compared to a previous normal state unrelated to an acute event, not meeting the criteria for mild cognitive impairment or dementia (see supporting information). In both cohorts, at least one essential SCD-plus criterion (i.e., concerns related to SCD) had to be met for inclusion. NC groups in both cohorts were within the normal range on cognitive tests and reported no self-perceived cognitive declines of concern. We selected SILCODE subjects aged ≥ 60 years to better comply with the inclusion criteria of DELCODE. All DELCODE SCD subjects were referred from memory clinics. SILCODE SCD subjects were partially recruited from memory clinics and advertisements.

The current analyses included baseline data of 218 SILCODE subjects (SILCODE$_{whole}$) and 531 DELCODE subjects (DELCODE$_{whole}$; Figure 1A) after magnetic resonance (MR) quality controls (MRIQC;[45] Figure S1; Tables S1, S2 in supporting information). In SILCODE$_{whole}$, $n = 68$ (57%) SCD were recruited from memory clinics. Amyloid-PET was available in 59 SILCODE SCD subjects (SILCODE$_{PET}$: $n = 39$ [66%] from memory clinics) and 59 DELCODE SCD subjects (DELCODE$_{PET}$). Both studies were approved by the responsible ethics committees and radiation protection authorities.[9,43] All participants provided written informed consent.

2.2 | Clinical and neuropsychological assessments

All subjects underwent cohort-specific standardized neuropsychological assessment probing episodic memory, executive function, and language, performing in the normal range at baseline.[44,46,47] Both cohorts applied the Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS),[48,49] and structured Subjective Cognitive Decline Interview (SCD-I).[44,50] Based on SCD-I, we summarized the number of SCD cognitive domains (SCD-domain) and the number of features potentially associated with an increased risk of cognitive decline in SCD (SCD-plus).[1,2] The latter includes (1) perceived decline in the memory domain, (2) onset of SCD within the last 5 years in persons aged over 60 years, (3) SCD-related concerns, and

FIGURE 1 Sample size and seed regions for the functional connectivity analyses. A, The number of subjects in each cohort and subcohort with amyloid PET. B, Illustration of the masks for the limbic ROIs derived from the Automated Anatomical Labeling atlas.[54] The cingulate ROI encompasses the anterior, middle, and posterior parts of the cingulate cortex. The composite-limbic ROI mask is composed of all limbic ROIs. L, left; NC, normal controls; PET, positron emission tomography; R, right; ROI, region of interest; SCD, subjective cognitive decline.

(4) feeling cognitively worse than peers. We omitted the feature informant confirmation[50] due to insufficient data in SILCODE$_{whole}$. We also report cohort-specific measures on episodic memory (SILCODE: Adult Verbal Learning Test [AVLT];[51] DELCODE:a composite memory score [MEM][47]), and anxiety symptoms (SILCODE: Hamilton Anxiety Rating Scale [HAMA];[52] DELCODE: Geriatric Anxiety Inventory–Short Form [GAI-SF][53]). Apolipoprotein E (*APOE*) genotype was obtained from both cohorts (see supporting information).

2.3 | MR and PET imaging

2.3.1 | Image acquisition

SILCODE magnetic resonance imaging (MRI) data were acquired with a single 3T scanner. DELCODE is a multicenter study with scanning protocols harmonized across 3T scanners of participating sites. Technical details for the T1-weighted anatomical and resting-state functional MRI (rs-fMRI) scans are presented in Table S3 in supporting information.

Amyloid-PET examinations were performed with ^{18}F-florbetapir (FBP, Eli Lilly) in SILCODE and ^{18}F-florbetaben (FBB, Life Radiopharma) in DELCODE at the nuclear medicine departments of the participating sites (for details see Table S4 in supporting information).

2.3.2 | Pre-processing of MRI data

Pre-processing of structural and rs-fMRI data was performed using SPM12, including motion correction, slice time correction, coregistration, normalization, detrending, smoothing, nuisance regression (motion, white matter, cerebrospinal fluid signals), and temporal bandpass filtering (0.01-0.1 Hz; see supporting information).

2.3.3 | Assessment of limbic FC

Masks for key limbic regions of interest (ROI; Figure 1B), including bilateral cingulate cortex, hippocampus, parahippocampal cortex,

amygdala, and thalamus, were created from the Automated Anatomical Labeling (AAL) atlas.[54] All limbic ROIs were also combined into a composite-limbic ROI mask.

DC values were calculated using GRETNA[55] at voxel level by quantifying the sum of the connectivity weights within a whole brain mask encompassing both limbic and non-limbic areas. The mean DC values within each limbic ROI[55,56] were standardized within each cohort (standard DC). It provides a global characterization of the importance of ROIs in the overall brain network[56] (Table S5 in supporting information).

sFC was calculated using GRETNA by assessing interregional connectivity between each limbic AAL ROI seed and the rest of the brain.[33,35,40] Here, the mean time series of each limbic ROI was correlated with each voxel of the entire brain to obtain the sFC maps, which were Fisher *z* transformed.

2.3.4 | PET Centiloid analyses

Cortical tracer binding of FBP in SILCODE$_{PET}$ and FBB in DELCODE$_{PET}$ was quantified using the Centiloid method[57] to derive standardized analyses of global cortical amyloid burden. SILCODE$_{PET}$ FBP data were analyzed in SPM12, while DELCODE$_{PET}$ FBB data were analyzed with PMOD 4.2 (PMOD Technologies LLC), after calibration using the validation datasets (see supporting information). To indicate early amyloid positivity, Centiloid ≥ 20 was used based on recent suggestions.[58]

2.4 | Statistical analysis

2.4.1 | Sample characteristics

Across the two cohorts, two-way analyses of variance (ANOVA) with cohort and group as main factors or chi-square tests were carried out for sample characteristics. For those variables that were only available for one cohort, two-sample *t* tests were performed to assess group differences within each cohort. Two-sample *t* tests or chi-square tests were applied for the SCD-only PET subcohorts to measure cohort

differences in sample characteristics and Centiloid values. A $P < 0.05$ was considered significant for all analyses.

2.4.2 | Group comparisons of limbic FC

Comparisons between SCD and NC groups were carried out in each cohort separately. The standard DC of each limbic ROI was defined as a dependent variable (DV) in a generalized linear model (GLIM) implemented using the "fitglm" function in MATLAB. The sFC map of each ROI was defined as the DV in an SPM12 general linear model (GLM). All models defined group as the independent variable, controlling for age, sex, years of education, *APOE* genotype, and scanner sites (DELCODE only).

For DC analyses, significant effects were determined at $P < 0.05$ (Bonferroni-corrected). For sFC analyses, whole brain cluster-level family-wise error (FWE) correction with $P < 0.05$ (primary height threshold $P < 0.001$, cluster extent > 200 voxels) was applied.

2.4.3 | Association between limbic FC and amyloid burden

Limbic DC values or sFC maps were defined as DV in separate models for each PET subcohort. Centiloid value was defined as an independent variable, and age, sex, years of education, and *APOE* genotype as covariates. No scanner covariates were included due to small sample sizes.[59] The same statistical threshold was set as in the whole-cohort analyses.

2.4.4 | Association between limbic FC and cognition/SCD characteristics

Based on the previous whole-cohorts analyses (section 2.4.2), commonly altered FC measures across cohorts were correlated (Pearson) with cognitive performance (MMSE, AVLT, MEM), and SCD characteristics (SCD-domain, SCD-plus). Subsequently, significant behavioral variables were added as DV in a series of GLIMs within each cohort to check for group-specific effects. Model 1 estimated DV with an FC measure, with age, sex, years of education, *APOE* genotype, and scanner sites (DELCODE only) as covariates. Model 2 fitted DV with FC measure + group + FC measure × group + covariates. In the case of a significant interaction in Model 2, model 3 tested the DV with FC measure + covariates in each diagnostic group. For these exploratory analyses, $P < 0.05$, uncorrected, was considered significant.

3 | RESULTS

3.1 | Sample characteristics

Both cohorts differed slightly in sample characteristics (Table 1; Table S6 in supporting information). DELCODE$_{whole}$ showed higher age, years of education, and SCD-domain scores than SILCODE$_{whole}$, with no cohort difference in SCD-plus scores and distribution of *APOE* ε4 carriers. In DELCODE$_{whole}$, SCD subjects had slightly worse episodic memory (MEM) than NC subjects, whereas SILCODE$_{whole}$ showed no group difference in episodic memory (AVLT). SILCODE$_{whole}$ had slightly higher GDS scores than DELCODE$_{whole}$. Both cohorts presented higher GDS scores, and also higher anxiety scores (HAMA or GAI-SF) in the SCD versus NC group.

For the SCD subcohorts with amyloid-PET, DELCODE$_{PET}$ showed higher age, years of education, Centiloid values, amyloid-PET positivity rate, and SCD-domain scores than SILCODE$_{PET}$ (Table 2; Table S7 in supporting information).

3.2 | Group differences in limbic FC

For SILCODE$_{whole}$, standard DC values in the composite-limbic ROI, cingulate cortex, hippocampus, and amygdala were significantly higher in the SCD group than in the NC group (Figure 2A; Table S8 in supporting information). For DELCODE$_{whole}$, DC values in the composite-limbic ROI, hippocampus, parahippocampal cortex, and amygdala were higher in the SCD group than in the NC group (Figure 2B; Table S8 in supporting information). This was observed irrespective of the absolute threshold selected for DC calculation (Table S9 in supporting information). The standard DC scores in composite-limbic ROI, hippocampus, and amygdala were consistently increased in the SCD group across the two cohorts. They were used for the following analyses of associations between the FC measures and behavioral variables (section 3.4).

In SILCODE$_{whole}$, the SCD group showed increased sFC strength between multiple limbic ROIs (hippocampus, amygdala) and insula/putamen compared to the NC group (Figure 3A; Table S10 in supporting information). The SCD group of DELCODE$_{whole}$ exhibited increased sFC strength between the hippocampus and a cluster encompassing the right insula/putamen, amygdala, and parahippocampal cortex (Figure 3B; Table S10 in supporting information). Both cohorts showed overlapping patterns of increased connectivity between hippocampus and right insula (Figure 3C). The mean sFC values extracted from the overlapping right insula region were used to analyze associations between the FC measures and the behavioral variables in both cohorts (section 3.4).

3.3 | Association between limbic FC and amyloid load

We observed no association between standard DC scores and Centiloid values in either PET subcohort (Table S11 in supporting information).

In both subcohorts, higher Centiloid values were associated with decreased sFC strength between limbic ROIs and non-limbic areas. In SILCODE$_{PET}$, reduced connectivity was found between the cingulate cortex and the temporoparietal junction (TPJ), including the left superior temporal gyrus and supramarginal gyrus (Figure 4A; Table S12 in supporting information). In DELCODE$_{PET}$, negative associations

TABLE 1 Sample characteristics in the whole cohorts.

Characteristic	SILCODE NC (n = 99)	SILCODE SCD (n = 119)	DELCODE NC (n = 199)	DELCODE SCD (n = 332)	Group effect (post hoc)	Cohort effect (post hoc)	Group × cohort (post hoc)
Age	66.65 ± 4.46	66.53 ± 4.59	69.38 ± 5.49	71.16 ± 6.09	F = 3.45	F = 67.16***	F = 4.48* (b***, c***, d***)
Sex (M/F)	42 / 57	37 / 82	82 / 117	180 / 152	$\chi^2 = 8.43^{\dagger**}$	$\chi^2 = 18.76^{\S***}$	/
Education	12.21 ± 2.91	12.66 ± 2.81	14.67 ± 2.71	14.80 ± 2.99	F = 1.53	F = 96.51***	F = 0.43
APOEε4 carriers (percentage)	13.13%	27.73%	21.10%	31.93%	$\chi^2 = 7.25^{\dagger***}$ $\chi^2 = 6.92^{\ddagger***}$	–	/
SCD-domain	1.17 ± 1.07	1.87 ± 1.01	1.50 ± 1.38	2.48 ± 1.33	F = 65.54*** (e***)	F = 20.60*** (f***)	F = 1.87
SCD-plus	1.27 ± 1.01	$2.97 \pm .74$	1.63 ± 1.49	2.61 ± 1.22	F = 183.66***	F = 0.001	F = 13.58*** (a, b***, c*, d**)
MMSE	29.04 ± 1.11	28.73 ± 1.22	29.47 ± 0.83	29.23 ± 1.00	F = 10.92** (e***)	F = 31.16*** (f***)	F = 0.23
GDS	1.79 ± 1.92	2.79 ± 2.36	0.64 ± 1.25	2.01 ± 2.06	F = 56.66*** (e***)	F = 38.37*** (f***)	F = 1.37
HAMA	2.94 ± 2.72	5.45 ± 3.90	/	/	$T = 5.39^{\ddagger***}$	/	/
AVLT (N1-3)	21.01 ± 4.67	20.55 ± 3.70	/	/	T = 0.98	/	/
AVLT (N4)	7.61 ± 1.93	7.24 ± 1.94	/	/	T = 1.41	/	/
AVLT (N5)	7.35 ± 2.14	7.11 ± 1.90	/	/	T = 0.89	/	/
AVLT-reco	22.66 ± 1.53	22.30 ± 1.58	/	/	T = 1.68	/	/
GAI-SF	/	/	0.70 ± 0.84	1.17 ± 1.20	$T = 4.78^{\dagger***}$	/	/
MEM	/	/	0.63 ± 0.45	0.39 ± 0.56	$T = 5.26^{\dagger***}$	/	/

NOTE. Data were presented as mean ± SD.

†Comparison between NC and SCD groups within DELCODE.

‡Comparison between NC and SCD groups within SILCODE.

§Comparison of the SCD groups between SILCODE and DELCODE cohorts.

aRepresents a significant difference between the NC and SCD groups in SILCODE.

bRepresents a significant difference between the NC and SCD groups in DELCODE.

cRepresents a significant difference in NC grossups between two cohorts.

dRepresents a significant difference in SCD groups between two cohorts.

eRepresents a significant difference between the NC and SCD groups regardless of cohorts.

fRepresents a significant difference between the SILCODE and the DELCODE cohorts regardless of groups.

/Data were not available.

-Results were not significant.

*P < 0.05.

**P < 0.01.

***P < 0.001.

Abbreviations: APOE, apolipoprotein E; AVLT (N1-3), Auditory Verbal Learning Test: the sum of first three learning trials; AVLT (N4), Auditory Verbal Learning Test: 5 minute short-term delayed recall; AVLT (N5), Auditory Verbal Learning Test: 20 minute long-term delayed recall; AVLT-reco, Auditory Verbal Learning Test: recognition; DELCODE, DZNE Longitudinal Cognitive Impairment and Dementia; F, female; GAI-SF, Geriatric Anxiety Inventory–Short Form; GDS, Geriatric Depression Scale; HAMA, Hamilton Anxiety Rating Scale; M, male; MEM, episodic memory composition score; MMSE, Mini-Mental State Examination; NC, normal controls; SCD, subjective cognitive decline; SD, standard deviation; SILCODE, Sino Longitudinal Study on Cognitive Decline.

between amyloid burden and sFC between the composite-limbic and parahippocampal ROIs and bilateral and left cerebellum, respectively, were observed (Figure 4B; Table S12 in supporting information).

3.4 | Association between limbic FC and cognition/SCD characteristics

SCD-plus scores were significantly associated with limbic DC scores in SILCODE and with sFC between hippocampus and insula in both cohorts. No further associations were found (Table S13 in supporting information). The GLIMs for SCD-plus with additional covariates reproduced the correlation results. The models with FC × group interaction showed significant group effects for all models and almost all significant interactions except the amygdala DC of DELCODE. Further within-group analyses revealed positive effects of all FC measures on SCD-plus scores in the SILCODE NC, but not in the SCD. In DELCODE, positive effects of hippocampal DC and hippocampal-insula sFC on SCD-plus were also found in the NC group but not in the SCD group (Table S14 in supporting information).

FIGURE 2 Group effects on the global limbic functional connectivity. Higher standard degree of connectivity (DC) values in the SCD group compared to the NC group in (A) SILCODE$_{whole}$ and (B) DELCODE$_{whole}$. Bonferroni-corrected, *, $P < 0.05$; **, $P < 0.01$. Amyg, amygdala; Centiloid, standardized Centiloid values representing global amyloid burden; Cing, cingulate; Comp, composite-limbic ROI; DELCODE, DZNE Longitudinal Cognitive Impairment and Dementia; Hipp, hippocampus; NC, normal controls; Para, parahippocampal cortex; ROI, region of interest; SCD, subjective cognitive decline; SILCODE, Sino Longitudinal Study on Cognitive Decline; Thal, thalamus.

4 | DISCUSSION

The current study identified consistently increased global connectivity of limbic regions across two large independent SCD cohorts from Western and Eastern populations. Furthermore, interregional connectivity between the hippocampus and right insular cortex was found to be increased in both SCD cohorts relative to their respective control groups. Results thus suggest initial adaptions in limbic FC in SCD defined by contemporary research criteria,[1,2] regardless of ethnic and cultural backgrounds. There was limited evidence that FC changes were related to amyloid burden in SCD participants with additional PET scans, leaving open whether these functional alterations are directly related to AD neuropathology. For the first time, we demonstrated that applying current SCD research definitions to Western and Eastern populations identifies overlapping functional network changes. Yet, these definitions may need further refinement to enrich preclinical AD in Chinese SCD populations and would require further research into unraveling culture-specific SCD features.

The present study made substantial efforts to align the inclusion criteria for SCD participants from two ethnic cohorts. Apart from the identical general SCD definition[1] and using the same structured questionnaire (SCD-I), both cohorts recruited SCD subjects with the key feature of concerns regarding cognitive decline. This may have contributed to our consistent cross-ethnic findings of increased limbic DC scores and hippocampus–insula connectivity in SCD. Indeed, patterns of the increased network nodal property (e.g., DC) in the hippocampus[27,28] and increased interregional connectivity between the hippocampus and insula[31] were previously reported in either Western or Eastern SCD populations. Hence, our results suggest that increased hippocampal FC in SCD should be deemed a robust finding that is valid across different ethnic and cultural backgrounds.

The insula cortex is a core region of the salience network and may be critically involved in self-awareness.[60] Hyperconnectivity between hippocampus and insula may specifically reflect increased awareness of cognitive decline in SCD.[31] In contrast, reduced connectivity of these two regions was observed in dementia patients who

had become anosognosic for their memory deficits.[61] In the current study, increased hippocampus-insula connectivity consistently predicted higher SCD-plus scores in the pooled SCD and NC groups across both cohorts. Yet, post hoc analyses showed that hippocampus–insula connectivity predicted SCD-plus in NC but not SCD groups of both cohorts. Although our NC subjects did not report cognitive decline of concern, higher levels of hippocampus–insula connectivity in the presence of relatively increased SCD-plus scores (e.g., feeling cognitively worse than peers) may reflect subclinical variation in the individual awareness of cognitive deterioration. Meanwhile, the lack of complementary associations within the SCD groups may be due to ceiling effects on the SCD-plus measure. Future studies should attempt to stratify SCD subjects into different levels of self-awareness of cognition and investigate the related FC changes (e.g., using metacognition approaches[12]).

Alternatively, increased connectivity is frequently interpreted as a compensatory phenomenon,[17,53] assuming that vulnerable brain regions work harder by excessively increasing connectivity.[62] Here, one might expect positive relationships between FC increases and cognitive measures, which was not supported by the present data (Table S13 in supporting information). Moreover, explorative analyses did not show that the overlapping hippocampal–insular FC increases were linked with regional gray matter volume (and potential atrophic changes) in the hippocampus, and in the respective insular areas (Table S13 in supporting information).

This is further supported by the lack of positive associations between Centiloid values and any limbic FC measures, in either PET subcohort (Tables S11, S12 in supporting information). Accordingly, we found no direct evidence that the common FC increases were essentially driven by amyloid pathology. In the reverse direction, there were cohort-specific observations linking higher Centiloid levels to reduced sFC connectivity between the cingulate cortex and TPJ in SILCODE, and between the parahippocampal/composite-limbic ROIs and bilateral cerebellum in DELCODE. They may reflect detrimental effects of amyloid deposition in these brain networks. Similar oppositional patterns of hippocampal and parietal FC changes were previously

(A) Group effects in SILCODEwhole

(B) Group effects in DELCODEwhole

(C) Common Group effects in SILCODEwhole and DELCODEwhole

FIGURE 3 Group effects on the functional connectivity between limbic areas and other brain areas. Increased seed-based functional connectivity (sFC) between each ROI and the rest of the brain in SCD compared to NC in (A) the SILCODE$_{whole}$ cohort, and (B) the DELCODE$_{whole}$ cohort. The clusters indicated with red circles were significant at $P_{FWE} < 0.05$ (whole brain cluster-level corrected, primary height threshold $P < 0.001$, cluster extent > 200 voxels). For display purposes, the clusters in (A) and (B) were thresholded at $P_{FWE} < 0.05$ (whole brain cluster-level corrected, primary height threshold $P < 0.005$, cluster extent > 500 voxels). C, The group effects that overlapped between two cohorts; red, the overlap at the height threshold of $P < 0.001$; yellow, the overlap at the height threshold of $p < 0.005$. ***, $P < 0.001$. Amyg, amygdala; DELCODE, DZNE Longitudinal Cognitive Impairment and Dementia; FWE, family-wise error; Hipp, hippocampus; INS, insula; L, left; NC, normal controls; PUT, putamen; R, right; ROI, region of interest; SCD, subjective cognitive decline; SILCODE, Sino Longitudinal Study on Cognitive Decline.

(A) Amyloid load effects in SILCODE~PET~

(B) Amyloid load effects in DELCODE~PET~

FIGURE 4 Amyloid load effects on the seed-based functional connectivity (sFC). Negative associations between Centiloid values and mean sFC values in (A) SILCODE~PET~ and (B) DELCODE~PET~. All clusters were significant at $P_{FWE} < 0.05$ (whole brain cluster-level corrected, primary height threshold $P < 0.001$, cluster extent > 200 voxels). For display purposes, the clusters were thresholded at $P_{FWE} < 0.05$ (whole brain cluster-level corrected, primary height threshold $P < 0.005$, cluster extent > 500 voxels). Centiloid, standardized Centiloid values representing global amyloid burden; CERE, cerebellum; Cing, cingulate cortex; Comp, composite-limbic ROI; DELCODE, DZNE Longitudinal Cognitive Impairment and Dementia; FWE, family-wise error; L, left; Para, parahippocampal cortex; R, right; ROI, region of interest; SMG, supramarginal gyrus; SILCODE, Sino Longitudinal Study on Cognitive Decline; STG, superior temporal gyrus.

observed in SCD,[27] indicating that both up- and downregulation of brain networks may already occur in SCD. The present Centiloid associations should be interpreted with caution: Amyloid-PET was only available for some SCD participants, and a restricted number of cases met conventional amyloid positivity cut-offs, especially in SILCODE. Although not representative of the whole sample, this might suggest a more heterogeneous etiology in the Chinese compared to the German SCD cohort. This may be partially explained by age differences between the PET subcohorts, given general age-related increases in amyloid positivity rates.[63] It would also concur with recent observations of lower amyloid-PET positive rates in Asian versus White Americans with cognitive impairments.[64] Finally, our cross-sectional

data allow no directional inferences (i.e., amyloid burden driving FC, or vice versa[16]).

There were additional cohort-specific findings, for example, sFC group comparisons, which revealed increased amygdala–insula connectivity in SCD versus NC in SILCODE, but not DELCODE. Generally, cohort-specific results could be related to ethnic diversity in functional connectomics per se[38] and disease-induced adaptations, respectively.

While restricting analyses to participants ≥60 years,[1] SILCODE subjects were still younger than DELCODE on average, which may be influenced by general cultural differences, such as a lack of health literacy regarding neurodegenerative diseases[65] and a higher acceptance of cognitive decline[6,66] in China. Examining the main effects of the

TABLE 2 Sample characteristics in the SCD subcohorts with amyloid PET imaging.

Characteristic	SILCODE$_{PET}$ (n = 59)	DELCODE$_{PET}$ (n = 59)	Comparison
Age	66.29 ± 4.56	71.76 ± 6.06	T = 5.55 ***
Sex (M/F)	16 / 43	21 / 38	χ^2 = 0.98
Education	12.54 ± 2.74	15.53 ± 3.03	T = 5.60 ***
APOEε4 carriers (percentage)	30.51%	38.98%	χ^2 = 0.93
Centiloid	−3.27 ± 18.80	25.60 ± 34.01	T = 5.71***
Aβ+ (percentage)	8.47 %	37.29%	χ^2 = 13.88***
SCD domains	1.98 ± 1.04	2.73 ± 1.05	T = 3.88***
SCD plus	2.93 ± 0.76	2.92 ± 0.86	T = 0.11
MMSE	29.07 ± 1.23	29.25 ± 1.12	T = 0.86
GDS	2.46 ± 2.06	2.01 ± 1.89	T = 1.26
HAMA	4.86 ± 3.85	/	/
AVLT (N1-3)	21.61 ± 3.62	/	/
AVLT (N4)	7.66 ± 2.03	/	/
AVLT (N5)	7.68 ± 2.11	/	/
AVLT-reco	22.33 ± 1.03	/	/
GAI-SF	/	1.05 ± 1.02	/
MEM	/	.43 ± 0.59	/

NOTE: Data were presented as mean ± SD.

/Data were not available.

***$P < 0.001$.

Abbreviations: Aβ+: Rate of amyloid-positive cases with Centiloid ≥ 20;[59] APOE, apolipoprotein E; AVLT (N1-3), Auditory Verbal Learning Test: the sum of first three learning trials; AVLT (N4), Auditory Verbal Learning Test: 5 minute short-term delayed recall; AVLT (N5), Auditory Verbal Learning Test: 20 minute long-term delayed recall; AVLT-reco, Auditory Verbal Learning Test: recognition; Centiloid, standardized Centiloid values representing global amyloid burden according to Klunk et al.[58] DELCODE, DZNE Longitudinal Cognitive Impairment and Dementia; F, female; GAI-SF, Geriatric Anxiety Inventory–Short Form; GDS, Geriatric Depression Scale; HAMA, Hamilton Anxiety Rating Scale; HAMD, Hamilton Depression Rating Scale; M, male; MEM, memory assessment; MMSE, Mini-Mental State Examination; PET, positron emission tomography; SCD, subjective cognitive decline; SD, standard deviation; SILCODE, Sino Longitudinal Study on Cognitive Decline.

age covariates in our statistical models, we found no overlap with our primary findings (Tables S15-S18 in supporting information). Therefore, age differences between cohorts are unlikely to affect the main findings.

While DELCODE only included memory clinic SCD patients, SILCODE partially recruited via advertisements, reflecting fundamental differences in primary health care (see supporting information): German family practice–based primary care is currently not affordable in China, making medical service via internet a critical complementary approach.[67] We also performed secondary analyses using the memory clinic SCD subgroup in SILCODE, which confirmed our main findings (see Table S19 in supporting information), suggesting that the source

of SCD recruitment did not impact the current results, although this needs to be tested explicitly in future studies.

For the first time, we demonstrated overlapping functional brain network changes in both Eastern and Western populations when applying the current SCD research definition. Yet, this definition may not achieve the same level of enrichment of preclinical AD in the Chinese SCD population as in the German SCD population, although such inferences are preliminary due to the small sample size of SCD individuals with amyloid-PET. Our findings regarding commonly increased global limbic connectivity and hippocampus–insula connectivity in SCD may reflect a heightened awareness of cognitive decline, irrespective of underlying AD pathology. Future studies need to investigate the possible underlying cause of Chinese SCD, such as neuropsychiatric symptoms, vascular disease, or social factors, and to identify culturally specific features[64] to achieve enrichment of preclinical AD and guide future treatment and prevention.

AFFILIATIONS

[1] Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China

[2] German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

[3] Key Laboratory of Biomedical Engineering of Hainan Province, School of Biomedical Engineering, Hainan University, Haikou, China

[4] Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany

[5] Department of Neurology, University of Bonn, Bonn, Germany

[6] University of Bonn Medical Center, Department of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, Bonn, Germany

[7] German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

[8] Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany

[9] Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Goettingen, Germany

[10] German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany

[11] Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany

[12] Department for Psychiatry and Psychotherapy, University Clinic Magdeburg, Magdeburg, Germany

[13] Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany

[14] Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany

[15] Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany

[16] Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany

[17] Department of Psychiatry & Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, Texas, USA

[18] German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany

[19] Department of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany

[20] German Center for Neurodegenerative Diseases (DZNE), Tuebingen, Germany

[21] Department of Psychiatry and Psychotherapy, University of Tuebingen, Tuebingen, Germany

[22]Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin-Institute of Psychiatry and Psychotherapy, Berlin, Germany

[23]Berlin Center for Advanced Neuroimaging, Charité – Universitätsmedizin Berlin, Berlin, Germany

[24]MR-Research in Neurosciences, Department of Cognitive Neurology, Georg-August-University Goettingen, Goettingen, Germany

[25]German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

[26]Department for Biomedical Magnetic Resonance, University of Tuebingen, Tuebingen, Germany

[27]Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

[28]Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

[29]Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany

[30]Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Germany

[31]Institute of Neuroscience and Medicine (INM-2), Molecular Organization of the Brain, Forschungszentrum Jülich, Germany

[32]Department of Nuclear Medicine, Ludwig-Maximilian-University Munich, Munich, Germany

[33]Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland

[34]Department of Nuclear Medicine, Rostock University Medical Centre, Rostock, Germany

[35]Department of Nuclear Medicine and Clinical Molecular Imaging, Eberhard-Karls-University, Tuebingen, Germany

[36]School of Medicine, Technical University of Munich, Department of Psychiatry and Psychotherapy, Munich, Germany

[37]University of Edinburgh and UK DRI, Edinburgh, UK

[38]German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany

[39]Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal

[40]Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany

[41]Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK

[42]Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tuebingen, Tuebingen, Germany

[43]Institute of Biomedical Engineering, Shanghai University, Shanghai, China

[44]Clinical Functional Imaging Group, Department of Diagnostic and Interventional Radiology, University Hospital Bonn, Bonn, Germany

[45]Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, China

[46]National Clinical Research Center for Geriatric Disorders, Beijing, China

ACKNOWLEDGMENTS

CONFLICT OF INTEREST STATEMENT

The authors declare no conflicts of interest. Author disclosures are available in the supporting information.

CONSENT STATEMENT

All human subjects provided informed consent.

ORCID

Xueyan Jiang https://orcid.org/0000-0002-5231-2677

Xiaochen Hu https://orcid.org/0000-0003-4126-673X

Marcel Daamen https://orcid.org/0000-0002-3017-3901

Enise I. Incesoy https://orcid.org/0000-0003-2014-4098

Boris-Stephan Rauchmann https://orcid.org/0000-0003-4547-6240

Alfredo Ramirez https://orcid.org/0000-0003-4991-763X

Ingo Kilimann https://orcid.org/0000-0002-3269-4452

Matthias H. Munk https://orcid.org/0000-0002-5339-4045

Luisa-Sophie Schneider https://orcid.org/0000-0001-5822-1744

Stefan Hetzer https://orcid.org/0000-0002-1773-1518

Michael Ewers https://orcid.org/0000-0003-1856-9337

Klaus Scheffler https://orcid.org/0000-0001-6316-8773

Holger Amthauer https://orcid.org/0000-0003-4414-0657

Ralph Buchert https://orcid.org/0000-0002-0945-0724

Alexander Drzezga https://orcid.org/0000-0001-6018-716X

Axel Rominger https://orcid.org/0000-0002-1954-736X

Bernd J. Krause https://orcid.org/0000-0002-2572-4131

Josef Priller https://orcid.org/0000-0001-7596-0979

Anja Schneider https://orcid.org/0000-0001-9540-8700

Jens Wiltfang https://orcid.org/0000-0003-1492-5330

Robert Perneczky https://orcid.org/0000-0003-1981-7435

Oliver Peters https://orcid.org/0000-0003-0568-2998

Emrah Düzel https://orcid.org/0000-0002-0139-5388

Michael Wagner https://orcid.org/0000-0003-2589-6440

Jiehui Jiang https://orcid.org/0000-0003-4948-3683

Frank Jessen https://orcid.org/0000-0003-1067-2102

Henning Boecker https://orcid.org/0000-0003-2346-0598

Ying Han https://orcid.org/0000-0003-0377-7424

REFERENCES

1. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. *Alzheimers Dement.* 2014;10(6):844-852. doi: 10.1016/j.jalz.2014.01.001

2. Jessen F, Amariglio RE, Buckley RF, et al. The characterisation of subjective cognitive decline. *Lancet Neurol*. 2020;19(3):271-278. doi: 10.1016/S1474-4422(19)30368-0

3. Jack CR Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018

4. Slot RER, Sikkes SAM, Berkhof J, et al. Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia. *Alzheimers Dement*. 2019;15(3):465-476. doi: 10.1016/j.jalz.2018.10.003

5. Janssen O, Jansen WJ, Vos SJB, et al. Characteristics of subjective cognitive decline associated with amyloid positivity. *Alzheimers Dement*. 2021. doi: 10.1002/alz.12512

6. Wu Q. Subjective cognitive impairment of older adults: a comparison between the US and China. *Int J Methods Psychiatr Res*. 2016;25(1):68-75. doi: 10.1002/mpr.1499

7. Molinuevo JL, Rabin LA, Amariglio R, et al. Implementation of subjective cognitive decline criteria in research studies. *Alzheimers Dement*. 2017;13(3):296-311. doi: 10.1016/j.jalz.2016.09.012

8. Sino-German Center. Accessed March 30, 2023. <http://sinogermanscience.dfg.nsfc.cn/de/aktuelles/2016/201611/t20161128_489245.html; http://sinogermanscience.dfg.nsfc.cn/de/aktuelles/de_2017/201711/t20171122_489271.html; http://sinogermanscience.dfg.nsfc.cn/de/aktuelles/de_2019/201912/t20191204_489320.html>

9. Li X, Wang X, Su L, Hu X, Han Y. Sino Longitudinal Study on Cognitive Decline (SILCODE): protocol for a Chinese longitudinal observational study to develop risk prediction models of conversion to mild cognitive impairment in individuals with subjective cognitive decline. *BMJ Open*. 2019;9(7):e028188. doi: 10.1136/bmjopen-2018-028188

10. Pan FF, Huang Q, Wang Y, et al. Non-linear character of plasma amyloid beta over the course of cognitive decline in Alzheimer's continuum. *Front Aging Neurosci*. 2022;14:832700. doi: 10.3389/fnagi.2022.832700

11. Chen Q, Lu J, Zhang X, et al. Alterations in dynamic functional connectivity in individuals with subjective cognitive decline. *Front Aging Neurosci*. 2021;13:646017. doi: 10.3389/fnagi.2021.646017

12. Li Q, Sun X, Cui L, et al. Alterations in metamemory capacity and neural correlates in a subtype of subjective cognitive decline. *Neuroimage Clin*. 2022;36:103255. doi: 10.1016/j.nicl.2022.103255

13. Wang X, Bi Q, Lu J, et al. Difference in amyloid load between single memory domain and multidomain subjective cognitive decline: a Study from the SILCODE. *J Alzheimers Dis*. 2022;85(4):1573-1582. doi: 10.3233/JAD-215373

14. Li Q, Pan FF, Huang Q, Lo CZ, Xie F, Guo Q. Altered metamemory precedes cognitive impairment in subjective cognitive decline with positive amyloid-beta. *Front Aging Neurosci*. 2022;14:1046445. doi: 10.3389/fnagi.2022.1046445

15. Brettschneider J, Del Tredici K, Lee VM, Trojanowski JQ. Spreading of pathology in neurodegenerative diseases: a focus on human studies. *Nat Rev Neurosci*. 2015;16(2):109-120. doi: 10.1038/nrn3887

16. Jones DT, Knopman DS, Gunter JL, et al. Cascading network failure across the Alzheimer's disease spectrum. *Brain*. 2016;139(2):547-562. doi: 10.1093/brain/awv338

17. Catani M, Dell'acqua F, Thiebaut de Schotten M. A revised limbic system model for memory, emotion and behaviour. *Neurosci Biobehav Rev*. 2013;37(8):1724-1737. doi: 10.1016/j.neubiorev.2013.07.001

18. Acosta-Cabronero J, Nestor PJ. Diffusion tensor imaging in Alzheimer's disease: insights into the limbic-diencephalic network and methodological considerations. *Front Aging Neurosci*. 2014;6:266. doi: 10.3389/fnagi.2014.00266

19. Skouras S, Torner J, Andersson P, et al. Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation. *Brain*. 2020;143(3):976-992. doi: 10.1093/brain/awaa011

20. Whitwell JL, Shiung MM, Przybelski SA, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. *Neurology*. 2008;70(7):512-520. doi: 10.1212/01.wnl.0000280575.77437.a2

21. Hu X, Uhle F, Fliessbach K, et al. Reduced future-oriented decision making in individuals with subjective cognitive decline: a functional MRI study. *Alzheimers Dement (Amst)*. 2017;6:222-231. doi: 10.1016/j.dadm.2017.02.005

22. Hafkemeijer A, Altmann-Schneider I, Oleksik AM, et al. Increased functional connectivity and brain atrophy in elderly with subjective memory complaints. *Brain Connect*. 2013;3(4):353-362. doi: 10.1089/brain.2013.0144

23. Hu X, Teunissen CE, Spottke A, et al. Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies. *Alzheimers Dement*. 2019;15(2):185-193. doi: 10.1016/j.jalz.2018.09.002

24. Mosconi L, De Santi S, Brys M, et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. *Biol Psychiatry*. 2008;63(6):609-618. doi: 10.1016/j.biopsych.2007.05.030

25. Vannini P, Hanseeuw B, Munro CE, et al. Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden. *Neurology*. 2017;88(18):1759-1767. doi: 10.1212/WNL.0000000000003889

26. Viviano RP, Damoiseaux JS. Functional neuroimaging in subjective cognitive decline: current status and a research path forward. *Alzheimers Res Ther*. 2020;12(1):23. doi: 10.1186/s13195-020-00591-9

27. Li K, Luo X, Zeng Q, et al. Aberrant functional connectivity network in subjective memory complaint individuals relates to pathological biomarkers. *Transl Neurodegener*. 2018;7:27. doi: 10.1186/s40035-018-0130-z

28. Xie Y, Liu T, Ai J, et al. Changes in centrality frequency of the default mode network in individuals with subjective cognitive decline. *Front Aging Neurosci*. 2019;11:118. doi: 10.3389/fnagi.2019.00118

29. Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, et al. Subjective cognitive decline is associated with altered default mode network connectivity in individuals with a family history of Alzheimer's Disease. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2018;3(5):463-472. doi: 10.1016/j.bpsc.2017.11.012

30. Chen H, Sheng X, Luo C, et al. The compensatory phenomenon of the functional connectome related to pathological biomarkers in individuals with subjective cognitive decline. *Transl Neurodegener*. 2020;9(1):21. doi: 10.1186/s40035-020-00201-6

31. Attaallah B, Petitet P, Slavkova E, et al. Hyperreactivity to uncertainty is a key feature of subjective cognitive impairment. *Elife*. 2022;11. doi: 10.7554/eLife.75834

32. Wang Y, Risacher SL, West JD, et al. Altered default mode network connectivity in older adults with cognitive complaints and amnestic mild cognitive impairment. *J Alzheimers Dis*. 2013;35(4):751-760. doi: 10.3233/JAD-130080

33. Yasuno F, Kazui H, Yamamoto A, et al. Resting-state synchrony between the retrosplenial cortex and anterior medial cortical structures relates to memory complaints in subjective cognitive impairment. *Neurobiol Aging*. 2015;36(6):2145-2152. doi: 10.1016/j.neurobiolaging.2015.03.006

34. Dillen KNH, Jacobs HIL, Kukolja J, et al. Functional disintegration of the default mode network in prodromal Alzheimer's disease. *J Alzheimers Dis*. 2017;59(1):169-187. doi: 10.3233/JAD-161120

35. Viviano RP, Hayes JM, Pruitt PJ, et al. Aberrant memory system connectivity and working memory performance in subjective cognitive decline. *Neuroimage*. 2019;185:556-564. doi: 10.1016/j.neuroimage.2018.10.015

36. Amaefule CO, Dyrba M, Wolfsgruber S, et al. Association between composite scores of domain-specific cognitive functions and regional patterns of atrophy and functional connectivity in the Alzheimer's disease spectrum. *Neuroimage Clin.* 2021;29:102533. doi: 10.1016/j.nicl.2020.102533

37. Li J, Bzdok D, Chen J, Tam A, et al. Cross-ethnicity/race generalization failure of behavioral prediction from resting-state functional connectivity. *Sci Adv.* 2022;8(11):eabj1812. doi: 10.1126/sciadv.abj1812

38. Ge J, Yang G, Han M, et al. Increasing diversity in connectomics with the Chinese Human Connectome Project. *Nat Neurosci.* 2023;26(1):163-172. doi: 10.1038/s41593-022-01215-1

39. Chiesa PA, Cavedo E, Grothe MJ, et al. Relationship between basal forebrain resting-state functional connectivity and brain amyloid-beta deposition in cognitively intact older adults with subjective memory complaints. *Radiology.* 2019;290(1):167-176. doi: 10.1148/radiol.2018180268

40. Li S, Daamen M, Scheef L, et al. Abnormal regional and global connectivity measures in subjective cognitive decline depending on cerebral amyloid status. *J Alzheimers Dis.* 2021;79(2):493-509. doi: 10.3233/JAD-200472

41. Chiesa PA, Cavedo E, Vergallo A, et al. Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. *Alzheimers Dement.* 2019;15(7):940-950. doi: 10.1016/j.jalz.2019.03.006

42. Zhou Y, Wang Y, Blanco-Hinojo L, et al. Anomalous brain functional connectivity contributing to poor adaptive behavior in Down syndrome. *Cortex.* 2015;64:148-156. doi: 10.1016/j.cortex.2014.10.012

43. Jessen F, Spottke A, Boecker H, et al. zheimer's disease (DELCODE). *Alzheimers Res Ther.* 2018;10(1):15. doi: 10.1186/s13195-017-0314-2

44. Jessen F, Wolfsgruber S, Kleineindam L, et al. Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers. *Alzheimers Dement.* 2022. doi: 10.1002/alz.12674

45. Esteban O, Birman D, Schaer M, Koyejo OO, Poldrack RA, Gorgolewski KJ. MRIQC: advancing the automatic prediction of image quality in MRI from unseen sites. *PLoS One.* 2017;12(9):e0184661. doi: 10.1371/journal.pone.0184661

46. Sheng C, Yang K, He B, et al. Cross-Cultural Longitudinal Study on Cognitive Decline (CLoCODE) for Subjective Cognitive Decline in China and Germany: a Protocol for Study Design. *J Alzheimers Dis.* 2022. doi: 10.3233/JAD-215452

47. Wolfsgruber S, Kleineidam L, Guski J, et al. Minor neuropsychological deficits in patients with subjective cognitive decline. *Neurology.* 2020;95(9):e1134-e1143. doi: 10.1212/WNL.0000000000010142

48. Gauggel S, Birkner B. Validity and reliability of a German version of the Geriatric Depression Scale (GDS). *Zeitschrift fur Klinische Psychologie-Forschung und Praxis.* 1999;28(1):18-27.

49. Xie Z, Lv X, Hu Y, et al. Development and validation of the geriatric depression inventory in Chinese culture. *Int Psychogeriatr.* 2015;27(9):1505-1511. doi: 10.1017/S1041610215000162

50. Miebach L, Wolfsgruber S, Polcher A, et al. Which features of subjective cognitive decline are related to amyloid pathology? Findings from the DELCODE study. *Alzheimers Res Ther.* 2019;11(1):66. doi: 10.1186/s13195-019-0515-y

51. Zhao Q, Lv Y, Zhou Y, Hong Z, Guo Q. Short-term delayed recall of auditory verbal learning test is equivalent to long-term delayed recall for identifying amnestic mild cognitive impairment. *PLoS One.* 2012;7(12):e51157. doi: 10.1371/journal.pone.0051157

52. Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. *J Affect Disord.* 1988;14(1):61-68. doi: 10.1016/0165-0327(88)90072-9

53. Byrne GJ, Pachana NA. Development and validation of a short form of the Geriatric Anxiety Inventory–the GAI-SF. *Int Psychogeriatr.* 2011;23(1):125-131. doi: 10.1017/S1041610210001237

54. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage.* 2002;15(1):273-289. doi: 10.1006/nimg.2001.0978

55. Wang J, Wang X, Xia M, Liao X, Evans A, He Y. GRETNA: a graph theoretical network analysis toolbox for imaging connectomics. *Front Hum Neurosci.* 2015;9:386. doi: 10.3389/fnhum.2015.00386

56. Zuo XN, Ehmke R, Mennes M, et al. Network centrality in the human functional connectome. *Cereb Cortex.* 2012;22(8):1862-1875. doi: 10.1093/cercor/bhr269

57. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. *Alzheimers Dement.* 2015;11(1):1-15. doi: 10.1016/j.jalz.2014.07.003. e11-14.

58. Rafii MS, Sperling RA, Donohue MC, et al. The AHEAD 3-45 Study: design of a prevention trial for Alzheimer's disease. *Alzheimers Dement.* 2022. doi: 10.1002/alz.12748

59. Harrell FE. *Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis.* Springer; 2001.

60. Lou HC, Changeux JP, Rosenstand A. Towards a cognitive neuroscience of self-awareness. *Neurosci Biobehav Rev.* 2017;83:765-773. doi: 10.1016/j.neubiorev.2016.04.004

61. Berlingeri M, Ravasio A, Cranna S, et al. Unrealistic representations of "the self": a cognitive neuroscience assessment of anosognosia for memory deficit. *Conscious Cogn.* 2015;37:160-177. doi: 10.1016/j.concog.2015.08.010

62. Reuter-Lorenz PA, Cappell KA. Neurocognitive aging and the compensation hypothesis. *Curr Dir Psychol Sci.* 2008;17(3):177-182.

63. Jansen WJ, Janssen O, Tijms BM, et al. Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum. *JAMA Neurol.* 2022;79(3):228-243. doi: 10.1001/jamaneurol.2021.5216

64. Wilkins CH, Windon CC, Dilworth-Anderson P, et al. Racial and ethnic differences in amyloid PET positivity in individuals with mild cognitive impairment or dementia: a secondary analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study. *JAMA Neurol.* 2022;79(11):1139-1147. doi: 10.1001/jamaneurol.2022.3157

65. Yang T, Huang Y, Li X, et al. Knowledge, attitudes, and stigma related to dementia among illiterate and literate older adults in Shanghai. *Risk Manag Healthc Policy.* 2021;14:959-966. doi: 10.2147/RMHP.S296044

66. Lockenhoff CE, De Fruyt F, Terracciano A, et al. Perceptions of aging across 26 cultures and their culture-level associates. *Psychol Aging.* 2009;24(4):941-954. doi: 10.1037/a0016901

67. Li X, Krumholz HM, Yip W, et al. Quality of primary health care in China: challenges and recommendations. *Lancet.* 2020;395(10239):1802-1812. doi: 10.1016/S0140-6736(20)30122-7

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.